Dutch enforcer issues first excessive pricing fine
The Dutch competition authority has fined Leadiant Biosciences €17.9 million for charging excessively high prices for a drug used to treat a rare genetic metabolic disorder, marking the first time it has ever imposed a penalty for such an infringement.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.